Conference Day One
Wednesday 15th March 2023
8:00 am Registration & Welcome Coffee
8:25 am Chair’s Opening Remarks
Reviewing Glioblastoma Clinical Updates in the Past Year: The Successes & Failures
8:30 am Examining the Current Landscape of Glioblastoma Therapies & Strategies to Improve Outcomes
Synopsis
- Overview of novel therapies for GBM in development
- Understanding reasons for past failures
- Evaluating strategies to improve the identification of more effective therapies
9:00 am Panel Discussion: GBM AGILE Goes Worldwide: Taking a Deep Dive Into How Well It Has Worked So Far & What Promise It Brings With Expansion
Synopsis
- Reflecting on more than 3 years of progress – lessons learned to date and plans/goals for the next 3+ years
- Stakeholder perspectives – industry, clinical/scientific investigators, and patient advocates
- Adaptive Global Innovative Learning Environment (AGILE): Focusing on the “LE” in AGILE
9:30 am Bizaxofusp in rGBM Patients Versus a Propensity Matched External Control Arm: Designing a Novel Phase 3 Trial with the FDA
Synopsis
- Present design, mechanism, delivery and safety of bizaxofusp, an IL-4/IL-13R empowered superkine
- Summarize Phase 2b trial comparing bizaxofusp versus a propensity matched external control arm and effect of MGMT methylation, dose, IL4R expression, and combination with bevacizumab on median survival
- Overview of a novel Phase 3 registration trial using a Hybrid External Control Arm
10:00 am Tinostamustine: A Novel Alkylator – First Data in Glioblastoma
Synopsis
- Introducing Tinostamustine as a glioblastoma therapeutic
- Analyzing the development program and preliminary results of MDACC Phase I IIT
- Testing tinostamustine in a Phase I GBM study in Europe
10:15 am Berubicin, An Anthracycline Analogue That Crosses the BBB, For The Treatment of GBM
Synopsis
- Overview of the preclinical and Phase 1 clinical results of Berubicin in the treatment of GBM
- Synopsis and preliminary results of an ongoing clinical trial comparing Berubicin to Lomustine therapy for GBM after failure of first line treatment
- Review of safety and activity in this trial of Berubicin with the potential to establish a novel treatment strategy for GBM
10:45 am Speed Networking Break
Synopsis
This session is the ideal opportunity to introduce yourself to the attendees that
you would like to have more in-depth conversations with. Use this time to get
back to face-to-face interaction with many of the brightest minds working in the
glioblastoma field and establish meaningful business relationships.
11:45 am Immunization With Autologous Dendritic Cells is Associated With Extended Survival in Glioblastoma Patients
Synopsis
- Results of Phase III trial
- Novel trial design using external controls
- Mechanism of action of dendritic cell-based immunotherapy
- Manufacturing of autologous cell-based products
12:15 pm BMX-001: New Therapy Showing Increased Survival in Newly Diagnosed Glioblastoma
Synopsis
- New drug class – redox-active metallaporphyrins – positioned to transform the efficacy of radiation and chemotherapy in oncology
- Novel BMX-001 dual action enhances tumor killing while mitigating radiation-induced side-effects
- Discussion of ongoing randomized, 160 patient, multi-center trial
12:45 pm Lunch Break
Synopsis
Take this chance to meet the expert speakers, connect with your peers and explore our exhibition booths.
An Update On RANO 2.0 & Outlining Novel Imaging Endpoints in Phase II & III Clinical Trials
1:45 pm Assessing Response in Gliomas (RANO 2.0)
Synopsis
- Overview of the challenges of response assessment in gliomas
- Current data on optimal response assessment
- Review of RANO 2.0 for glioblastomas and other gliomas in adults
2:15 pm Delving Into Imaging Endpoint Strategies for Early & Later-stage Glioblastoma Clinical Trials
Synopsis
- For early phase clinical trials involving a limited number of patients and/or complex tumor types, a tiered approach to recognizing, quantifying, and interpreting radiographic changes is recommended, including the use of digital “flipbooks” and a modified Levin criterion, in order to increase confidence in potential therapeutic changes
- To increase the likelihood of success in later phase trials, we recommend evaluating the proportion of patients exhibiting a meaningful change in growth rate trajectory and progression-free survival (PFS), including calculation of pre-treatment growth rates and use of a “hyperacute” baseline within days of starting experimental therapy
- Historic data suggests objective response rate (ORR) >25%, in combination with a sufficient duration of response (DOR), leads to a meaningful increase in overall survival and a high likelihood of success in late-stage survival studies
2:45 pm ONC201 in Recurrent H3 K27M-mutant Diffuse Midline Glioma
Synopsis
- Overview of ONC201 discovery and early clinical development
- Review of efficacy signal refinement for ONC201 toward H3 K27M-mutant glioma
- Summary of ONC201 efficacy it recurrent H3 K27M-mutant diffuse midline glioma
3:15 pm Tissue Preservation for Optimized GBM TreatmentBullet Points:
Synopsis
- Reviewing the importance of tissue preservation for neuro-oncology patients
- Understanding the role of functional precision medicine in clinical practice
- Discussing opportunities for advanced preclinical model development
3:30 pm Afternoon Break
Synopsis
Take this chance to meet the expert speakers, connect with your peers and explore our exhibition booths.
Dodging the Side Effects & Risks of Glioblastoma Treatment Through Non-Invasive Therapies
4:00 pm Session Reserved for Kintara Therapeutics
4:30 pm Understanding the World of MR-Guided Focussed Ultrasounds- Translating This Approach Into Glioblastomas
Synopsis
- Unpacking the biological principles of Magnetic Resonance-guided Focused Ultrasounds (MRgFUS) in treating tumors
- Exploring how MRgFUS has been successful in treating other pathologies like uterine cancers
- Evaluating how feasible and effective this would be as a treatment for glioblastomas
4:45 pm Laser Interstitial Thermal Therapy: A Novel Technique to Treat Notoriously Hard-to-Reach GBM Tumors
Synopsis
- Discovering the principles of Laser Interstitial Thermal Therapy (LITT)
- Spotlighting how this approach is useful for patients who are resistant to stereotactic radiosurgery or suffer from radiation necrosis
- Gaining an insight into a clinician’s perspective of how effective LITT is in practicality
5:00 pm The impact of Tumor-Treating Fields on glioblastoma residual disease
Synopsis
- Providing an overview of the biological and biophysical effects of Tumor-Treating Fields (TTFields)
- Describing laboratory tools to investigate the impact of TTFields in vitro and in vivo
- Discussing the antiproliferative effects of TTFields on tumor cells isolated from glioblastoma residual disease
5:30 pm Sonodynamic Therapy: A Promising Approach to Targeting the Treatment of High-Grade Glioma
Synopsis
- Discussing the mechanism of action of sonodynamic therapy
- Analyzing the use of sonodynamic in high grade glioma
- Looking at the next steps for the use of sonodynamic therapy in high grade glioma
6:00 pm Chair’s Closing Remarks & End of Day One
6:00 pm Poster Networking Session
Synopsis
After the formal presentations have finished, the scientific Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere.
Continue to forge new and cement existing relationships while learning about the latest developments and breakthroughs in this field.